Open-Label Extension Study of Trofinetide for Rett Syndrome
ACADIA Pharmaceuticals Inc.n = 778 Nov 2020 to 30 Jun 2023
Rett Syndrome
PepBank has 31 trofinetide studies with results. All of them gave trofinetide, with 204 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 204 results and 58 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Trofinetide is an analog of the IGF-1 N-terminal tripeptide Gly-Pro-Glu. Its therapeutic mechanism in Rett syndrome is unknown.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
3 amino acids · 1 modification
Calculated from the two sequences. Curated notes are shown as given.
2 of 3 aligned residues identical (67%) · 1 non-canonical residue · Insulin-like growth factor 1 1–3
Differences from the parent
Basis: Trofinetide is an analog of Gly-Pro-Glu, the N-terminal tripeptide of mature IGF-1. It contains 2-methyl-L-proline at residue 2. P05019 identifies the parent protein, not trofinetide. Parent coordinates remain unset.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
3 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 11318905(opens in a new tab)
C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)OPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
31 of 58 studies have results (53%), published 2009 to 2026. Top row: every study. Bottom row: studies with results about Trofinetide, by class. The rows use different scales.
Studies58 in all, 2009 to 2026
Studies with results31 in all, 2009 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
13 trials match. Highest phase first. Data from ClinicalTrials.gov.
13 trials · 1 not yet recruiting · 9 completed · 3 stopped early · 4 with posted results
Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration
NCT01420042Feb 2012 to Sept 2012
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
NCT02100150Sept 2014 to Jun 2016
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
NCT041817236 Nov 2019 to 28 Oct 2021
13 trials · 1 not yet recruiting · 9 completed · 3 stopped early · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)
ACADIA Pharmaceuticals Inc.n = 778 Nov 2020 to 30 Jun 2023
Rett Syndrome
ACADIA Pharmaceuticals Inc.n = 1522 Sept 2021 to 31 May 2023
Rett Syndrome
ACADIA Pharmaceuticals Inc.n = 15429 Jan 2020 to 19 Aug 2022
Rett Syndrome
ACADIA Pharmaceuticals Inc.n = 1876 Nov 2019 to 28 Oct 2021
Rett Syndrome
Neuren Pharmaceuticals Limitedn = 82Mar 2016 to 5 Jan 2017
Rett Syndrome
Neuren Pharmaceuticals Limitedn = 261Apr 2010 to Jan 2016
Brain Injuries
Neuren Pharmaceuticals Limitedn = 261Feb 2013 to Jan 2016
Brain Injuries
Neuren Pharmaceuticals Limitedn = 67Mar 2013 to Sept 2014
Rett Syndrome
Neuren Pharmaceuticals Limitedn = 72Jan 2014 to Oct 2015
Fragile X Syndrome
Neuren Pharmaceuticals Limitedn = 32Sept 2014 to Jun 2016
Concussion
Neuren Pharmaceuticals Limitedn = 39Mar 2010 to Sept 2010
Brain Injuries, Traumatic
Neuren Pharmaceuticals Limitedn = 24Feb 2012 to Sept 2012
Brain Injuries, Traumatic
Colorado State Universityn = 60est. 1 Aug 2026 to est. 31 May 2028
Rett Syndrome · Family Caregivers · Social Support · Psychological Support
1 more mentions it but does not test it. They are not trials of Trofinetide: they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
58 studies match. Retracted studies are left out.
Showing 25 of 58 studiesquery qry_c69c60850d49ed47a99b0b21
31 studies in all, 18 on this page
Randomized controlled trial · 2023
Neul et al. 2023Nature medicinen = 187cited by 154
PMID 37291210PMC10287558DOI 10.1038/s41591-023-02398-1PUB-37291210
Randomized controlled trial · 2019
Glaze et al. 2019Neurologycited by 113
PMID 30918097PMC6550498DOI 10.1212/wnl.0000000000007316PUB-30918097
Randomized controlled trial · 2017
Glaze et al. 2017Pediatric neurologycited by 81
PMID 28964591DOI 10.1016/j.pediatrneurol.2017.07.002PUB-28964591
Animal study (in vivo) · rat · 2009
Wei et al. 2009Journal of neuroinflammationcited by 61
PMID 19656406PMC2731085DOI 10.1186/1742-2094-6-19PUB-19656406
Animal study (in vivo) · mouse · 2015
Deacon et al. 2015Neuromolecular medicinecited by 55
PMID 25613838DOI 10.1007/s12017-015-8341-2PUB-25613838
Animal study (in vivo) · rat · 2009
Bickerdike et al. 2009Journal of the neurological sciencescited by 46
PMID 19157421DOI 10.1016/j.jns.2008.12.003PUB-19157421
Animal study (in vivo) · rat · 2009
Lu et al. 2009Journal of neurotraumacited by 42
PMID 19119917DOI 10.1089/neu.2008.0629PUB-19119917
Randomized controlled trial · 2020
Berry-Kravis et al. 2020Pediatric neurologycited by 35
PMID 32660869DOI 10.1016/j.pediatrneurol.2020.04.019PUB-32660869
Animal study (in vivo) · rat · 2009
Lu et al. 2009Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolismcited by 27
PMID 19638995DOI 10.1038/jcbfm.2009.109PUB-19638995
Animal study (in vivo) · 2013
Cartagena et al. 2013Neuromolecular medicinecited by 27
PMID 23765588DOI 10.1007/s12017-013-8236-zPUB-23765588
Non-randomized trial · 2024
Percy et al. 2024Med (New York, N.Y.)n = 154cited by 25
PMID 38917793DOI 10.1016/j.medj.2024.05.018PUB-38917793
Randomized controlled trial · 2024
Neul et al. 2024Pediatric neurologycited by 22
PMID 38232652DOI 10.1016/j.pediatrneurol.2023.11.005PUB-38232652
Non-randomized trial · 2024
Percy et al. 2024Med (New York, N.Y.)n = 77cited by 20
PMID 39025065DOI 10.1016/j.medj.2024.06.007PUB-39025065
Randomized controlled trial · 2022
Darwish et al. 2022Clinical drug investigationn = 41cited by 13
PMID 35622206PMC9188616DOI 10.1007/s40261-022-01156-4PUB-35622206
Observational study · 2017
Oosterholt et al. 2017European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciencesn = 61cited by 12
PMID 28522374DOI 10.1016/j.ejps.2017.05.032PUB-28522374
Observational study · 2026
Cosand et al. 2026Developmental medicine and child neurologycited by 12
PMID 40936177PMC12875184DOI 10.1111/dmcn.16482PUB-40936177
Non-randomized trial · 2024
Darwish et al. 2024Clinical drug investigationcited by 7
PMID 38017349PMC10769996DOI 10.1007/s40261-023-01322-2PUB-38017349
Non-randomized trial · 2025
Percy et al. 2025Med (New York, N.Y.)n = 15cited by 7
PMID 40043705DOI 10.1016/j.medj.2025.100608PUB-40043705
23 studies in all, 7 on this page
PubMed tag: Clinical Trial Protocol · 2022
Neul et al. 2022Contemporary clinical trialscited by 54
PMID 35149233DOI 10.1016/j.cct.2022.106704PUB-35149233
PubMed tag: brief-report · 2023
Furqan et al. 2023Frontiers in pharmacologycited by 13
PMID 38035006PMC10687465DOI 10.3389/fphar.2023.1284035PUB-38035006
PubMed tag: brief-report · 2023
Kennedy et al. 2023Frontiers in pharmacologycited by 12
PMID 38318312PMC10839050DOI 10.3389/fphar.2023.1341746PUB-38318312
PubMed tag: none · 2025
Pozzer et al. 2025Brain : a journal of neurologycited by 11
PMID 39300821PMC11884770DOI 10.1093/brain/awae291PUB-39300821
PubMed tag: letter · 2023
Singh et al. 2023Intractable & rare diseases researchcited by 10
PMID 38024580PMC10680160DOI 10.5582/irdr.2023.01060PUB-38024580
PubMed tag: none · 2024
Aishworiya et al. 2024Focus (American Psychiatric Publishing)cited by 7
PMID 38680976PMC11046717DOI 10.1176/appi.focus.24022006PUB-38680976
PubMed tag: none · 2025
Ö et al. 2025International journal of molecular sciencescited by 7
PMID 41155297PMC12563243DOI 10.3390/ijms262010003PUB-41155297
Page 1 of 1
Neul JL · Nature medicine · 2023
Randomized controlled trial · 4 results
Neul JL · Pediatric neurology · 2024
Randomized controlled trial · 3 results
Darwish M · Clinical drug investigation · 2022
Randomized controlled trial · 8 results
Darwish M · Advances in therapy · 2026
Randomized controlled trial · 12 results
Glaze DG · Neurology · 2019
Randomized controlled trial · 5 results
Glaze DG · Pediatric neurology · 2017
Randomized controlled trial · 3 results
Berry-Kravis E · Pediatric neurology · 2020
Randomized controlled trial · 4 results
Percy AK · Med (New York, N.Y.) · 2024
Non-randomized trial · 8 results
Percy AK · Med (New York, N.Y.) · 2025
Non-randomized trial · 5 results
Percy AK · Med (New York, N.Y.) · 2024
Non-randomized trial · 6 results
Darwish M · European journal of drug metabolism and pharmacokinetics · 2025
Non-randomized trial · 4 results
Darwish M · Clinical drug investigation · 2024
Non-randomized trial · 17 results
Yu X · Frontiers in pharmacology · 2026
Observational study · 11 results
Rashid N · Journal of medical economics · 2026
Observational study · 11 results
Rashid N · International journal of general medicine · 2026
Observational study · 10 results
Oosterholt SP · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017
Observational study · 10 results
Prange EO · Frontiers in neurology · 2026
Observational study · 3 results
Rajagopalan K · Advances in therapy · 2026
Observational study · 4 results
Barrett AM · Clinical therapeutics · 2025
Observational study · 9 results
Cosand L · Developmental medicine and child neurology · 2026
Observational study · 10 results
Darwish M · Advances in therapy · 2024
Observational study · 4 results
Qian Z · PloS one · 2026
Observational study · 4 results
Li J · Clinical therapeutics · 2025
Observational study · 10 results
Jones SG · Journal of child neurology · 2026
Case report or series · 6 results
Wei HH · Journal of neuroinflammation · 2009
Animal study (in vivo) · rat · 8 results
Deacon RM · Neuromolecular medicine · 2015
Animal study (in vivo) · mouse · 1 result
Bickerdike MJ · Journal of the neurological sciences · 2009
Animal study (in vivo) · rat · 3 results
Lu XC · Journal of neurotrauma · 2009
Animal study (in vivo) · rat · 8 results
Cartagena CM · Neuromolecular medicine · 2013
Animal study (in vivo) · 6 results
Lu XC · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2009
Animal study (in vivo) · rat · 6 results
Chen M · Molecular neurobiology · 2025
Animal study (in vivo) · mouse · 3 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 27 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA |
| 27 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Not listed as banned by WADA Trofinetide and NNZ-2566 are not named in the 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
62 safety results for Trofinetide.
In females with Rett syndrome, diarrhea occurred in 80.6% receiving trofinetide versus 19.1% receiving placebo, mostly with mild-to-moderate severity.
Randomized controlled trialn = 187
In females with Rett syndrome receiving trofinetide in LILAC, diarrhea occurred in 74.7%.
Non-randomized trialn = 154
In females with Rett syndrome receiving trofinetide in LILAC, vomiting occurred in 28.6%.
Non-randomized trialn = 154
In females with Rett syndrome receiving trofinetide in LILAC, COVID-19 occurred in 11.0%.
Non-randomized trialn = 154
In females with Rett syndrome receiving trofinetide in LILAC, diarrhea led to treatment withdrawal in 21.4%.
Non-randomized trialn = 154
In females with Rett syndrome receiving trofinetide in LILAC-2, diarrhea occurred in 53.2%.
Non-randomized trialn = 77
In females with Rett syndrome receiving trofinetide in LILAC-2, COVID-19 occurred in 27.3%.
Non-randomized trialn = 77
In females with Rett syndrome receiving trofinetide in LILAC-2, vomiting occurred in 19.5%.
Non-randomized trialn = 77
The top 24 of 61 results.
The doses that these studies used. They are not recommendations.
12 g (60 mL oral solution)Human
12,000 mgHuman
200 mg/kg twice dailyHuman
70 mg/kg twice dailyHuman
70 mg/kg twice dailyHuman
6 g in moderate renal impairment; 12 g in healthy participantsHuman
6 of 22 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ trofinetideEvidence summary for Trofinetide: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| PharmacokineticsPharmacology | Human: 42 results from 6 studies: 1 increase, 12 no significant change, 29 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 42 |
| Adverse eventsWhole body | Human: 38 results from 12 studies: 5 increase, 2 no significant change, 31 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 38 |
| Treatment adherence and retentionPharmacology | Human: 25 results from 3 studies: 6 increase, 2 decrease, 17 not reported. Strongest design: Observational study | No results | No results | No results | 25 |
| Gastrointestinal adverse eventsGastrointestinal | Human: 22 results from 11 studies: 4 increase, 18 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 22 |
| Rett Syndrome SymptomsNervous system and cognition | Human: 12 results from 6 studies: 6 decrease, 6 not reported. Strongest design: Randomized controlled trial | No results | No results | Computer model: 1 result from 1 study: 1 decrease. Strongest design: In silico | 13 |
| CommunicationNervous system and cognition | Human: 10 results from 4 studies: 6 increase, 1 decrease, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 10 |
| Locomotor and behavioral activityNervous system and cognition | Human: 4 results from 1 study: 4 increase. Strongest design: Observational study | No results | No results | No results | 4 |
| Patient-reported outcomesWhole body | Human: 3 results from 3 studies: 3 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 3 |
| Exercise and physical functionNervous system and cognition | Human: 2 results from 1 study: 2 increase. Strongest design: Observational study | Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo) | No results | No results | 4 |
| Fragile X Syndrome SymptomsNervous system and cognition | Human: 2 results from 1 study: 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 2 |
| RTT symptomsNervous system and cognition | Human: 2 results from 2 studies: 2 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 2 |
| Treatment ExposurePharmacology | Human: 2 results from 1 study: 1 increase, 1 not reported. Strongest design: Observational study | No results | No results | No results | 2 |
12 outcome groups shown of 23 · 204 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
13 registered trials, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status.